469 related articles for article (PubMed ID: 12626555)
21. The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression.
Sánchez-Fueyo A; Domenig C; Strom TB; Zheng XX
Transplantation; 2002 Sep; 74(6):898-900. PubMed ID: 12364878
[TBL] [Abstract][Full Text] [Related]
22. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation.
Molano RD; Berney T; Li H; Cattan P; Pileggi A; Vizzardelli C; Kenyon NS; Ricordi C; Burkly LC; Inverardi L
Diabetes; 2001 Feb; 50(2):270-6. PubMed ID: 11272136
[TBL] [Abstract][Full Text] [Related]
23. Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation.
Xu H; Montgomery SP; Preston EH; Tadaki DK; Hale DA; Harlan DM; Kirk AD
J Immunol; 2003 Mar; 170(5):2776-82. PubMed ID: 12594309
[TBL] [Abstract][Full Text] [Related]
24. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation.
Kim EY; Lee EN; Lee J; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Joh JW; Kim SJ
Exp Mol Med; 2006 Jun; 38(3):284-94. PubMed ID: 16819287
[TBL] [Abstract][Full Text] [Related]
25. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody.
Welsh RM; Markees TG; Woda BA; Daniels KA; Brehm MA; Mordes JP; Greiner DL; Rossini AA
J Virol; 2000 Mar; 74(5):2210-8. PubMed ID: 10666251
[TBL] [Abstract][Full Text] [Related]
26. Prolonged survival of neonatal porcine islet xenografts in mice treated with a donor-specific transfusion and anti-CD154 antibody.
Appel MC; Banuelos SJ; Greiner DL; Shultz LD; Mordes JP; Rossini AA
Transplantation; 2004 May; 77(9):1341-9. PubMed ID: 15167588
[TBL] [Abstract][Full Text] [Related]
27. CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival.
Liu H; Qiu F; Wang Y; Zeng Q; Liu C; Chen Y; Liang CL; Zhang Q; Han L; Dai Z
Front Immunol; 2019; 10():306. PubMed ID: 30863408
[TBL] [Abstract][Full Text] [Related]
28. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival.
Gao W; Demirci G; Strom TB; Li XC
Transplantation; 2003 Sep; 76(6):994-9. PubMed ID: 14508368
[TBL] [Abstract][Full Text] [Related]
29. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression.
Adams AB; Durham MM; Kean L; Shirasugi N; Ha J; Williams MA; Rees PA; Cheung MC; Mittelstaedt S; Bingaman AW; Archer DR; Pearson TC; Waller EK; Larsen CP
J Immunol; 2001 Jul; 167(2):1103-11. PubMed ID: 11441122
[TBL] [Abstract][Full Text] [Related]
30. Without CD4 help, CD8 rejection of pig xenografts requires CD28 costimulation but not perforin killing.
Zhan Y; Brady JL; Sutherland RM; Lew AM
J Immunol; 2001 Dec; 167(11):6279-85. PubMed ID: 11714791
[TBL] [Abstract][Full Text] [Related]
31. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning.
Durham MM; Bingaman AW; Adams AB; Ha J; Waitze SY; Pearson TC; Larsen CP
J Immunol; 2000 Jul; 165(1):1-4. PubMed ID: 10861026
[TBL] [Abstract][Full Text] [Related]
32. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts.
Thornley TB; Brehm MA; Markees TG; Shultz LD; Mordes JP; Welsh RM; Rossini AA; Greiner DL
J Immunol; 2006 Feb; 176(3):1561-70. PubMed ID: 16424185
[TBL] [Abstract][Full Text] [Related]
33. Anti-mouse CD154 antibody treatment facilitates generation of mixed xenogeneic rat hematopoietic chimerism, prevents wasting disease and prolongs xenograft survival in mice.
Masaki H; Appel MC; Leahy L; Leif J; Paquin L; Shultz LD; Mordes JP; Greiner DL; Rossini AA
Xenotransplantation; 2006 May; 13(3):224-32. PubMed ID: 16756565
[TBL] [Abstract][Full Text] [Related]
34. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4.
Markees TG; Phillips NE; Gordon EJ; Noelle RJ; Shultz LD; Mordes JP; Greiner DL; Rossini AA
J Clin Invest; 1998 Jun; 101(11):2446-55. PubMed ID: 9616216
[TBL] [Abstract][Full Text] [Related]
35. Prolonged survival of rat islet and skin xenografts in mice treated with donor splenocytes and anti-CD154 monoclonal antibody.
Gordon EJ; Markees TG; Phillips NE; Noelle RJ; Shultz LD; Mordes JP; Rossini AA; Greiner DL
Diabetes; 1998 Aug; 47(8):1199-206. PubMed ID: 9703317
[TBL] [Abstract][Full Text] [Related]
36. Donor-Specific Regulatory T Cell-Mediated Immune Tolerance in an Intrahepatic Murine Allogeneic Islet Transplantation Model with Short-Term Anti-CD154 mAb Single Treatment.
Lee SJ; Kim HJ; Byun NR; Park CG
Cell Transplant; 2020; 29():963689720913876. PubMed ID: 32216448
[TBL] [Abstract][Full Text] [Related]
37. In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy.
Chen Y; Heeger PS; Valujskikh A
J Immunol; 2004 May; 172(9):5456-66. PubMed ID: 15100287
[TBL] [Abstract][Full Text] [Related]
38. Activation of alloreactive CD8+ T cells operates via CD4-dependent and CD4-independent mechanisms and is CD154 blockade sensitive.
Zhai Y; Meng L; Busuttil RW; Sayegh MH; Kupiec-Weglinski JW
J Immunol; 2003 Mar; 170(6):3024-8. PubMed ID: 12626556
[TBL] [Abstract][Full Text] [Related]
39. Immature syngeneic dendritic cells potentiate tolerance to pancreatic islet allografts depleted of donor dendritic cells in microgravity culture condition.
Stepkowski SM; Phan T; Zhang H; Bilinski S; Kloc M; Qi Y; Katz SM; Rutzky LP
Transplantation; 2006 Dec; 82(12):1756-63. PubMed ID: 17198272
[TBL] [Abstract][Full Text] [Related]
40. Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: implications for anti-CD154 immunotherapy.
van Maurik Av; Herber M; Wood KJ; Jones ND
J Immunol; 2002 Nov; 169(10):5401-4. PubMed ID: 12421913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
